There were mixed reactions across gene editing space on Thursday after CRISPR Therapeutics (NASDAQ: CRSP) and Vertex Pharmaceuticals (NASDAQ: VRTX), in a world’s first, won U.K. approval for their CRISPR-based drug exa-cel for sickle cell disease and beta-thalassemia.
CRISPR Therapeutics (CRSP) has added ~5%, and MaxCyte (NASDAQ: MXCT), which has a licensing deal with the Swiss biotech, has gained ~4%. Vertex Pharma (VRTX) is trading lower for the third straight session.
Other CRSPR-based drug developers Graphite Bio (GRPH) and Precision BioSciences (DTIL) are also among the gainers, while notable gene editing biotechs Editas Medicine (EDIT), Beam Therapeutics (BEAM), Intellia Therapeutics (NTLA), and Verve Therapeutics (VRTX) are in the red.
Leave a reply